Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands

摘要

596734 Disclosed is the use of a compound which selectively targets bothα4β2* andα6β2* for the manufacture of a medicament for treating, reducing, or delaying progression of L-dopa-induced dyskinesia or abnormal involuntary movements. Further disclosed is a combination comprising: a. L-dopa; and b. one or more compound, which selectively targets bothα4β2* andα6β2*.